Valeant spending $475 million to boost dermatology portfolio

3 February 2014

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) has entered into a definitive agreement to acquire USA-based PreCision Dermatology, for $475 million in cash, plus an additional $25 million payable upon the achievement of a sales-based milestone.

PreCision develops and markets dermatology products with leading products such as Locoid, Hylatopic, Clindagel, and BenzEFoam. PreCision expects to have around $130 million in revenue in 2014. The transaction is expected to close in the first half of 2014 and Valeant believes the transaction, once completed, to be immediately accretive to Valeant's cash earnings per share.

Valeant, which last year completed one of its biggest acquisitions, the $8.7 billion buy of eye-care specialist Bausch & Lomb, is projecting 2014 adjusted earnings of $8.25 to $8.75 a share and revenue of $8.2 billion to $8.6 billion. Last year, Valeant also bought skin-care product maker Obagi Medical Products for about $343.7 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK